Intellia Therapeutics, Inc. (0JBU)
London Exchange · UK · prices in USD · close of 23 Oct 2026
Key indicators
| Last close | USD 11.05 |
|---|---|
| 52-week range | 8.12 – 19.20 |
| Return, 1 month / 3 months | −8.8% / −1.7% |
| Return, 1 year / 3 years | – / – |
| Trend | Below its 200-day average |
| RSI (14) | 41 |
| Volatility (1 year) | 73.3% |
| Worst drawdown (1 year) | -40.1% |
| Average daily value traded | 0.25M USD |
| Dividend yield | – |
Market X-Ray price-based
Five-year price chart navy: price · brown: 200-day average
About the company
Intellia Therapeutics is a biotechnology company that develops gene editing medicines based on CRISPR technology. It works on treatments that edit genes inside the body and on approaches that modify cells outside the body before returning them to patients. Its research focuses on serious genetic and other diseases, including conditions affecting the heart, nerves and immune system. The company is based in Cambridge, Massachusetts, in the United States, and its work serves patients and clinicians through drug development partnerships and clinical studies.
On this site Intellia Therapeutics, Inc. appears as a stock on the London Exchange (UK), code 0JBU, with prices in US dollars (USD). Our records, which start in 2019, show no dividend payments for it. The Market X-Ray on this page is price-based and compares it with other stocks on the same exchange; it does not measure how healthy the business is.
Summary
Intellia Therapeutics, Inc. (0JBU) trades on the London Exchange in UK. It last closed at USD 11.05 on 23 October 2026.
Its price-based Market X-Ray is 27 out of 100 (a weak price profile), ranking 3,192 of 3,787 stocks on this exchange. The score describes how the stock has traded: trend, momentum, risk, liquidity and dividends, each ranked against the other stocks on its own exchange. It does not measure how healthy or cheap the business is.
Fundamental measures (valuation, growth, financial health) are not shown: we do not yet hold financial statements for this market.
The five lenses in numbers each metric is ranked against the other stocks on London Exchange
| Lens and metric | Value | Score | Reading |
|---|---|---|---|
| Trend | 22 · Weak | Below its long-term averages and far from its highs. | |
| Above 200-day average | -15.7% | ||
| From 52-week high | -38.0% | ||
| Momentum | 29 · Weak | Lagging most stocks on this exchange. | |
| 3-month return | -1.7% | ||
| 6-month return | -32.3% | ||
| 12-month return, skipping the last month | – | ||
| Stability (higher is calmer) | 22 · Weak | Volatile, with deep drawdowns. | |
| Volatility, 1 year (lower is calmer) | 73.3% | ||
| Worst drawdown, 1 year (smaller is calmer) | -40.1% | ||
| Liquidity | 39 · Weak | Thinly traded: prices can jump and exits can be hard. | |
| Average daily value traded | 0.25M USD | ||
| Zero-volume days | 0.0% | ||
| Income | – | Pays no dividend. | |
| Dividend yield | – | ||
| Years with dividends | 0 |
Strengths
No lens stands out as a clear strength against its exchange.
Weak spots
- Trend: Below its long-term averages and far from its highs.
- Momentum: Lagging most stocks on this exchange.
- Stability (higher is calmer): Volatile, with deep drawdowns.
- Liquidity: Thinly traded: prices can jump and exits can be hard.
Returns
| 1 week | +0.3% |
|---|---|
| 1 month | −8.8% |
| 3 months | −1.7% |
| 6 months | −32.3% |
| 1 year | – |
| 3 years | – |
| 5 years | – |
Signals
| 50-day / 200-day average | 12.21 / 13.11 |
|---|---|
| Golden / death cross (60 days) | None |
| New 52-week high | No |
| Bullish RSI divergence | No |
| Average daily range (ATR) | 0.73 |
Technical summary
How to read this report
Every number comes from end-of-day prices and dividends. The Market X-Ray describes how the stock has traded, ranked against the other stocks on London Exchange; it does not measure how healthy or cheap the business is. The fundamental X-Ray (financial health, valuation, growth) needs financial statements, which we hold today for US stocks. See the methodology page. Educational only, not financial advice.